Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dementia AND Galantamine (Reminyl) AND Galantamine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Dementia AND Galantamine (Reminyl) AND Galantamine. Displaying page 1 of 1.
    EudraCT Number: 2007-002780-27 Sponsor Protocol Number: GAL-ALZ-3005 Start Date*: 2008-08-26
    Sponsor Name:Janssen Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-severe Alzheimer’s Disease
    Medical condition: Mild to moderately severe Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) LT (Completed) LV (Prematurely Ended) EE (Prematurely Ended) CZ (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) AT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-006011-62 Sponsor Protocol Number: NL38747.048.11 Start Date*: 2012-02-08
    Sponsor Name:Slotervaart Hospital
    Full Title: The ACER-study - the effects of galantamine on the variability and stability of walking among patients with Alzheimer's disease.
    Medical condition: Dementia of the Alzheimer type
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013689-18 Sponsor Protocol Number: GALALZ4041 Start Date*: 2010-05-11
    Sponsor Name:Janssen-Cilag S.A.
    Full Title: ESTUDIO FASE IV PARA LA EVALUACIÓN DEL EFECTO MODULADOR DE LA GALANTAMINA (REMINYL CLP®) SOBRE EL RITMO CIRCADIANO DE PACIENTES CON ENFERMEDAD DE ALZHEIMER MODERADA
    Medical condition: Enfermedad de Alzheimer
    Disease: Version SOC Term Classification Code Term Level
    11 10012271 Demencia de tipo Alzheimer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-011093-15 Sponsor Protocol Number: 06173915 Start Date*: 2009-11-16
    Sponsor Name:Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology
    Full Title: The role of the neurotransmitters dopamine and acetylcholine in the interaction of selective attention and working memory.
    Medical condition: Healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    12.0 10012271 Dementia Alzheimer's type LLT
    12.0 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004335-36 Sponsor Protocol Number: ANAVEX2-73-PDD-001 Start Date*: 2018-07-04
    Sponsor Name:Anavex Life Sciences Corp.
    Full Title: A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients.
    Medical condition: Cognition in Parkinson’s Disease with dementia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002678-29 Sponsor Protocol Number: ANAVEX2-73-PDD-EP-001 Start Date*: 2019-12-05
    Sponsor Name:Anavex Life Sciences Corp.
    Full Title: Open Label Extension Study for Patients with Parkinson’s Disease with Dementia Previously Enrolled in ANAVEX2-73-PDD-001 Study for Continued Safety Assessment
    Medical condition: Cognition in Parkinson’s Disease with Dementia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 07:35:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA